EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States

Yulong He, Qinling Jiang, Xia Pan, Lin Deng, Xinrong Hu, Zhijian Yang, Wenwang Lang

Frontiers in Public Health · 06.07.2026 · 14

DOI: 10.3389/fpubh.2026.1781790 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Frontiers in Public Health, online erschienen am 06.07.2026. Verfasst von Yulong He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Bevacizumab, Liver Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Finotonlimab combined with bevacizumab demonstrated superior progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma. However, its economic value in different healthcare systems has not been fully characterized. This study evaluated the cost-effectiveness of finotonlimab plus bevacizumab from the perspectives of U.S. payers and the Chinese healthcare system. A Markov state-transition model was constructed using clinical efficacy data from a phase 3 randomized controlled trial.

Methods

Health state utilities were obtained directly from trial data, and cost inputs were derived from published sources and country-specific charge databases. The outcomes included quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net health benefits (INHBs), and incremental net monetary benefits (INMBs). Scenario analyses, deterministic and probabilistic sensitivity analyses, and price simulations were performed to assess the robustness and cost-effectiveness across predefined willingness-to-pay (WTP) thresholds.

Results

In the base-case analysis, the ICER of finotonlimab plus bevacizumab compared with sorafenib was $27,505.33 per QALY in China and $138,055.71 per QALY in the U.S., both below the corresponding WTP thresholds of $40,354.27 and $150,000 per QALY, respectively. The associated INHBs were 0.26 QALYs in China and 0.07 QALYs in the U.S., with INMBs of $10,523.82 and $10,684.73, respectively. Probabilistic sensitivity analysis indicated that combination therapy was cost-effective in 91.43% of simulations in China and 58.33% in the United States. Price simulation analyses suggested that finotonlimab would remain cost-effective in the U.S. setting when priced below $9,157.84 per 200 mg.

Conclusion

From both Chinese and U.S. payer perspectives, finotonlimab plus bevacizumab represents a cost-effective first-line treatment strategy for unresectable hepatocellular carcinoma. These findings offer quantitative support for pricing and reimbursement decisions related to this emerging immunotherapy combination targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibCarcinoma, HepatocellularBevacizumabLiver NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansCost-Benefit AnalysisUnited StatesChinaCost-Effectiveness AnalysisQuality-Adjusted Life YearsMarkov Chains

Stichwörter der Autor:innen

Markov modelbevacizumabcost-effectivenessfinotonlimabhepatocellular carcinomasorafenib

Substanzen

SorafenibBevacizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
  • Department of Hepatobiliary Surgery, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
  • Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.

Zitieren

APA

He, Y., Jiang, Q., Pan, X., Deng, L., Hu, X., Yang, Z., & Lang, W. (2026). Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1781790

Vancouver

He Y, Jiang Q, Pan X, Deng L, Hu X, Yang Z, et al. Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1781790

BibTeX
@article{He2026,
  author = {He, Yulong and Jiang, Qinling and Pan, Xia and Deng, Lin and Hu, Xinrong and Yang, Zhijian and Lang, Wenwang},
  title = {Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States},
  journal = {Frontiers in Public Health},
  year = {2026},
  volume = {14},
  doi = {10.3389/fpubh.2026.1781790}
}
Kostenlos starten →